Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools-Reference-Cited by-同舟云学术

Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools

Published:2017-01-11 Issue:372 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Lamberth Kasper¹,Reedtz-Runge Stine Louise¹,Simon Jonathan²,Klementyeva Ksenia²,Pandey Gouri Shankar²,Padkjær Søren Berg¹,Pascal Véronique¹,León Ileana R.¹,Gudme Charlotte Nini¹,Buus Søren³,Sauna Zuben E.²

Affiliation:

1. Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark.

2. Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.

3. Laboratory of Experimental Immunology, Faculty of Health Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.

Abstract

A computational and experimental strategy assesses the immunogenicity risk of bioengineered therapeutic proteins.

Funder

Oak Ridge Institute for Science and Education

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference29 articles.

1. Haemophilias A and B

2. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)